Skip To Main Content
Barbara Neudert on Muck Rack

Barbara Neudert

As seen in: Nature, Gastrointestinal Endoscopy, HPB
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility

|
By Daniel Valcanover, Barbara Neudert, Raheleh Sheibani-Tezerji, Theresa Mendrina, Jessica Kalla, Laura Pajed, Kristina Draganic, Andrea Haitel, Astrid D. Haase, Markus Hartenbach, Sazan Rasul, Walter Berger, Rolf Breinbauer, Gernot F. Grabner, Martina Schweiger, Eva M. Compérat, Gerda Egger, Andreas Tiefenbacher, Madeleine Gudenus
| Nature Verified
Abstract Despite the widespread clinical use of prostate-specific membrane antigen (PSMA)-targeted imaging and therapy in prostate cancer, the biological functions underlying PSMA-associated tumour aggressiveness remain incompletely understood. PSMA-PET-guided sampling of paired PSMA-high and PSMA-low tumour regions was used for integrated proteomic and epigenomic analyses. PSMA-ATGL correlation was validated by immunohistochemistry in 90 treatment-naïve patients.
Open in Who Shared Issue with article?

Tu1349 VARIATION OF THE IMMUNE CELL PROFILE IN YOUNG VERSUS AVERAGE-AGE SCREENING PARTICIPANTS WITH HIGH-RISK COLORECTAL CANCER PRECURSORS

|
By Florian Bognar, Thomas Sorz-Nechay, Barbara Neudert, Michael Trauner, Renate Kain, Monika Ferlitsch, Elisabeth Waldmann
| Gastrointestinal Endoscopy Verified
Also available on ScienceDirect
Open in Who Shared View Duplicates (401) Issue with article?

Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases

|
By Judith Stift, Alexandra Graf, Barbara Neudert, Merima Herac
| HPB Verified
Abstract Background The clinical value of immune checkpoint expression as prognostic biomarker in bevacizumab-pretreated patients with resected microsatellite-stable (MMS) colorectal liver metastases is unclear and was retrospectively investigated in this study. Methods Expression analyses of IDO-1, PD-L1, and CTLA-4 were performed by immunohistochemistry in resected bevacizumab-pretreated colorectal liver metastases.
Open in Who Shared Issue with article?
See all 3 articles